Navigation Links
Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinson's
Date:7/17/2008

el of PD-associated gastrointestinal (GI) dysfunction. She will use the model to test drugs that can alleviate this 'non-motor' symptom, which might also allow for better delivery of existing drugs such as levodopa that must pass through the GI tract to enter the bloodstream.

The following is a complete list of researchers who were awarded grants under Target Validation 2007. For grant abstracts and researcher bios, visit www.michaeljfox.org.

  • Roger J. Colbran, PhD, and Ariel Deutch, PhD,Vanderbilt University School of Medicine
    "CaMKII as a Therapeutic Target in Parkinson's Disease"

  • Ann M. Graybiel, PhD, Massachusetts Institute of Technology
    "Evaluation of the Striatum-enriched Genes CalDAG-GEF1 and CalDAG-GEF2 as Targets for the Treatment and Prevention of L-DOPA Induced Dyskinesia"

  • Pamela J. McLean, PhD, Massachusetts General Hospital (Harvard University)
    "Hsp90 as a Target for Neuroprotective Agents in Parkinson's Disease"

  • Kalipada Pahan, PhD, Rush University Medical Center
    "NBD Peptides in a Non-Human Primate Model of Parkinson's Disease"

  • Yvette F. Tache, PhD, University of California, Los Angeles
    "Mu Opioid Receptors as a Drug Target for Treating Motor Fluctuations in PD"

  • Malu G. Tansey, PhD, University of Texas Southwestern Medical Center
    "Dopaminergic Neuroprotection by Regulator of G-protein Signaling 10 (RGS10)"

  • Stephen F. Traynelis, PhD, and Stella Papa, MD, Emory University School of Medicine
    "Validation of the NR2D Subunit of the NMDA Receptor as a Therapeutic Target for Parkinson's Disease"

  • Danny G. Winder, PhD, Roger Colbran, PhD, and Eric Delpire, PhD, Vanderbilt University School of Medicine
    "NR2B as a Therapeutic Target in Parkinson's Disease"

  • Benjamin Wolozin, MD, PhD, Boston University School of Medicine
    "SIRT1 Activators as Therap
    '/>"/>

Contact: Holly Barkhymer
hbarkhymer@michaeljfox.org
212-509-0995 x242
The Michael J. Fox Foundation for Parkinson's Research
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related biology news :

1. Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors
2. American Society for Microbiology honors Michael Bruce Zwick
3. Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors
4. Remarks Prepared for Delivery By Attorney General Michael B. Mukasey At the Ministerial Press Conference
5. Neuroscientist Michael Gazzaniga awarded Humboldt Prize
6. Balzan Foundation announces 2007 winners
7. Keck Foundation funds study of biological interactions with nanomaterials
8. Yu receives research funding from the Wallace H. Coulter Foundation
9. PETA awards $120,000 to Duluth Foundation for advancing non-animal tests
10. Simons Foundation awards Emory scientists $3M for autism gene research
11. Arizona State University launches biofuel initiative with BP and Science Foundation Arizona
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)Coral reef fish can undergo a personality change in warmer water, according to an intriguing new study suggesting that climate change may make some species more aggressive. , Experiments with two spe
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
(Date:12/2/2009)PHILADELPHIA Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient,s future risk of death, according to published studies. Now, results of a ne
Breaking Biology News(10 mins):Fish with attitude: Some like it hot 2Grooving down the helix 2Grooving down the helix 3Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Smart Balance Announces 2009 Second Quarter Results 53838 1Smart Balance Announces 2009 Second Quarter Results 53838 2Smart Balance Announces 2009 Second Quarter Results 53838 3Smart Balance Announces 2009 Second Quarter Results 53838 4Smart Balance Announces 2009 Second Quarter Results 53838 5Smart Balance Announces 2009 Second Quarter Results 53838 6Smart Balance Announces 2009 Second Quarter Results 53838 7Smart Balance Announces 2009 Second Quarter Results 53838 8Smart Balance Announces 2009 Second Quarter Results 53838 9Smart Balance Announces 2009 Second Quarter Results 53838 10Oncothyreon announces webcast of second quarter 2009 financial results conference call 13414 1U S Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 53832 1U S Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 53832 2U S Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 53832 3
... Illinois at Chicago have identified an elusive su... humans and the much-studied laboratory nematode C...on muscle function. , The neurotransmitter acetylc...at the nematode,s neuromuscular junctions, causing...e subunit composition only of the levamisole-sensi...
...e molecule in the cell can serve as an advanced to...y may use a technique in which non-invasive magnet...olecule. The results of this research, conducted b...Biological Regulation Department, were published i...er with Dr. Batya Cohen of the Institute,s Molecul...
...ed at Johns Hopkins show that stem cell therapy ca...yocardial infarction, in pigs. In just two months,...ow and injected into the animal,s damaged heart re...uscle by 50 percent to 75 percent. , The Hopkins f...entific Sessions of the American Heart Association...
Other Biology News:Small worm yields big clue on muscle receptor action 2Novel live reporting system to track cells 2Stem cell therapy successfully treats heart attack in animals 2
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
(Date:12/2/2009)JERUSALEM, Israel, December 2 Gamida Cell announced today,a feasibility study evaluating the preclinical (animal study) safety and,efficacy of a gene therapy product which combines technology from We
(Date:12/2/2009)QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today annou
(Date:12/1/2009)Dr. Kerry Solomon announced that he has joined Carolina Eyecare Physicians and has launched his redesigned website at www.DrKerrySolomon.com , which was developed by Medical Consulting Group. Dr. So
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6
...is. - Building the Merge Healthcare of tomorrow...ains, will mean offshoring 150 jobs to a "more cos...duce 28 percent of the financially troubled medica...ed States, Canada, and Japan to regain the competi...anization initiative euphemistically labeled right...
...is. - TeraMedica , a medical informatics company...uct line, the VisLite Information Manager , an ...erability between clinical departments. , ,The pro...al medical images and connects them to existing el... also uses open standards in managing and storing ...
...is. - Quick quiz: Which Wisconsin institutions sp...fe sciences? , ,Naming No. 1 is relatively easy: t...) is perennially among the top academic R&D center... Medical College of Wisconsin ($139 million), whi...ch centers. Next up is the University of Wisconsi...
Other Biology Technology:Merge offshoring jobs to "more cost-effective" workforce 2Merge offshoring jobs to "more cost-effective" workforce 3Marshfield Clinic and UW combine to speed tech growth 2Marshfield Clinic and UW combine to speed tech growth 3Marshfield Clinic and UW combine to speed tech growth 4
PPase-2A from Promega
Mouse Anti-Salmonella typhimurium Monoclonal Antibody, Unconjugated, Clone 8C11C from ABR-Affinity BioReagents
AgarACE Enzyme from Promega
TNT® T7 Quick Coupled Transcription/Translation System from Promega
Biology Products: